Sanofi Adds mRNA Specialist Tidal To Acquisition Spree

Focus Again On Cancer and Immunology

 
• By Andrew McConaghie

Sanofi has paid out $160m to add to its in-house expertise in mRNA and novel cell therapy technologies.

Sanofi building
Sanofi has made a string of acquisitions in the last 18 months, acquiring early and mid-stage companies and assets.

More from Business

More from Scrip